China’s National Healthcare Security Administration (NHSA) has announced plans to compile a new catalog of innovative drugs aimed at making high-value medicines more accessible and affordable.
The catalog will serve as a reference for commercial insurers and other stakeholders within the country’s multi-level medical insurance system.
This initiative addresses the challenge of high drug prices and limited basic insurance coverage for newly developed treatments.
According to NHSA official Huang Xinyu, the effort will balance affordability for patients with protection of pharmaceutical innovation.
The new catalog will be developed alongside the ongoing updates to the existing drug list, which has added 853 new drugs over the past seven years.
Author
